Compare VCYT & CNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VCYT | CNS |
|---|---|---|
| Founded | 2006 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.1B |
| IPO Year | 2013 | 2004 |
| Metric | VCYT | CNS |
|---|---|---|
| Price | $43.60 | $61.01 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 2 |
| Target Price | $45.38 | ★ $72.50 |
| AVG Volume (30 Days) | ★ 959.1K | 547.7K |
| Earning Date | 11-04-2025 | 01-21-2026 |
| Dividend Yield | N/A | ★ 4.07% |
| EPS Growth | N/A | ★ 18.87 |
| EPS | 0.38 | ★ 3.19 |
| Revenue | $495,141,000.00 | ★ $552,096,000.00 |
| Revenue This Year | $16.02 | $8.26 |
| Revenue Next Year | $10.74 | $10.55 |
| P/E Ratio | $114.90 | ★ $19.13 |
| Revenue Growth | ★ 16.41 | 11.13 |
| 52 Week Low | $22.61 | $58.80 |
| 52 Week High | $50.71 | $102.17 |
| Indicator | VCYT | CNS |
|---|---|---|
| Relative Strength Index (RSI) | 51.98 | 39.97 |
| Support Level | $45.68 | $59.81 |
| Resistance Level | $48.10 | $64.43 |
| Average True Range (ATR) | 2.25 | 1.65 |
| MACD | -0.41 | 0.08 |
| Stochastic Oscillator | 41.56 | 39.11 |
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
Cohen & Steers is a niche asset manager concentrating on real estate securities. The firm invests mainly in the equity shares of real estate investment trusts, with holdings in domestic and international real estate securities accounting for around two thirds of its $90.9 billion in managed assets at the end of September 2025. Cohen & Steers also manages portfolios dedicated to preferred securities, utilities stocks, and other high-yield offerings. The firm's distribution is balanced among its closed-end funds, open-end funds, and institutional accounts. During the past four calendar quarters, the company garnered 39% (26%) of its managed assets (base management fees) from institutional clients, 48% (54%) from open-end funds, and 13% (20%) from closed-end funds.